Skip to main content
. 2021 Oct;10(10):3929–3942. doi: 10.21037/tlcr-21-524

Figure 1.

Figure 1

Treatment timelines (A) and progression-free survival of immunotherapy (B) in our cohort. , numbers of cycles of ICIs used till discontinuation for any causes. PR, partial response; SD, stable disease; PD, progression disease; nabPTX, nanoparticle albumin-bound paclitaxel; AC, pemetrexed + carboplatin; ICIs, immune checkpoint inhibitors; PFS, progression-free survival.